10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CLCS (Cell Source Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cell Source Inc together

I guess you are interested in Cell Source Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cell Source Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cell Source Inc’s Price Targets

I'm going to help you getting a better view of Cell Source Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cell Source Inc

I send you an email if I find something interesting about Cell Source Inc.

1. Quick Overview

1.1. Quick analysis of Cell Source Inc (30 sec.)










1.2. What can you expect buying and holding a share of Cell Source Inc? (30 sec.)

How much money do you get?

How much money do you get?
$113,065.18
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$-0.36
Expected worth in 1 year
$-0.63
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$113,064.91
Return On Investment
38,987,899.8%

For what price can you sell your share?

Current Price per Share
$0.29
Expected price per share
$0.2322 - $0.368
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cell Source Inc (5 min.)




Live pricePrice per Share (EOD)
$0.29
Intrinsic Value Per Share
$-0.70 - $-0.35
Total Value Per Share
$-1.06 - $-0.71

2.2. Growth of Cell Source Inc (5 min.)




Is Cell Source Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$15.6m-$12.6m-$2.9m-19.1%

How much money is Cell Source Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.1m-$5.1m0.000.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Cell Source Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#824 / 872

Most Revenue
#734 / 872

Most Profit
#420 / 872

Most Efficient
#300 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cell Source Inc?

Welcome investor! Cell Source Inc's management wants to use your money to grow the business. In return you get a share of Cell Source Inc.

First you should know what it really means to hold a share of Cell Source Inc. And how you can make/lose money.

Speculation

The Price per Share of Cell Source Inc is $0.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cell Source Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cell Source Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.36. Based on the TTM, the Book Value Change Per Share is $-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $28,266.30 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cell Source Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.12-41.0%-0.12-41.0%-0.15-50.2%-0.14-47.4%-0.13-45.4%-0.10-33.3%
Usd Book Value Change Per Share-0.07-23.6%-0.07-23.6%-0.06-22.3%-0.06-20.3%-0.05-17.0%-0.04-12.4%
Usd Dividend Per Share28,266.309,746,998.6%28,266.309,746,998.6%0.000.0%9,422.103,248,999.5%13,105.684,519,200.6%7,591.032,617,597.3%
Usd Total Gains Per Share28,266.239,746,974.9%28,266.239,746,974.9%-0.06-22.3%9,422.043,248,979.3%13,105.634,519,183.7%7,591.002,617,584.9%
Usd Price Per Share0.46-0.46-0.85-0.86-1.14-0.70-
Price to Earnings Ratio-3.87--3.87--5.84--6.12--8.70--7.31-
Price-to-Total Gains Ratio0.00-0.00--13.16--14.27--8.56--10.31-
Price to Book Ratio-1.28--1.28--2.92--3.29--5.83--4.12-
Price-to-Total Gains Ratio0.00-0.00--13.16--14.27--8.56--10.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.29
Number of shares3448
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share28,266.3013,105.68
Usd Book Value Change Per Share-0.07-0.05
Usd Total Gains Per Share28,266.2313,105.63
Gains per Quarter (3448 shares)97,461,951.8045,188,221.42
Gains per Year (3448 shares)389,847,807.18180,752,885.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1389848752-945389847797180753564-678180752876
2779697504-1890779695604361507128-1357361505762
31169546256-28341169543411542260692-2035542258648
41559395008-37791559391218723014257-2714723011534
51949243760-47241949239025903767821-3392903764420
62339092512-566923390868321084521385-40711084517306
72728941264-661327289346391265274949-47491265270192
83118790016-755831187824461446028513-54281446023078
93508638768-850335086302531626782077-61061626775964
103898487520-944838984780601807535641-67851807528850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%2.010.00.016.7%
Dividend per Share1.00.00.0100.0%1.00.02.033.3%3.00.02.060.0%4.00.06.040.0%4.00.08.033.3%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%6.06.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cell Source Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.069-0.0690%-0.065-6%-0.059-14%-0.049-28%-0.036-48%
Book Value Per Share---0.359-0.3590%-0.291-19%-0.292-19%-0.238-34%-0.177-51%
Current Ratio--0.0120.0120%0.031-61%0.025-50%0.030-58%0.039-68%
Debt To Asset Ratio--80.98980.9890%31.826+154%48.377+67%42.945+89%37.905+114%
Debt To Equity Ratio----0%-0%-0%-0%-0%
Dividend Per Share--28266.29628266.2960%-+100%9422.099+200%13105.682+116%7591.032+272%
Enterprise Value--4210861.0004210861.0000%23904230.000-82%24583682.733-83%38903810.040-89%29287117.900-86%
Eps---0.119-0.1190%-0.146+22%-0.138+16%-0.132+11%-0.097-19%
Ev To Ebitda Ratio---1.009-1.0090%---6.182+513%-11.110+1002%-7.913+685%
Free Cash Flow Per Share---0.054-0.0540%-0.072+34%-0.068+26%-0.065+21%-0.058+7%
Free Cash Flow To Equity Per Share---0.005-0.0050%0.003-255%-0.002-63%0.000-30761%0.000-100%
Gross Profit Margin--504040.360504040.3600%1.000+50403936%168014.120+200%100808.872+400%50404.975+900%
Intrinsic Value_10Y_max---0.346----------
Intrinsic Value_10Y_min---0.698----------
Intrinsic Value_1Y_max---0.053----------
Intrinsic Value_1Y_min---0.069----------
Intrinsic Value_3Y_max---0.145----------
Intrinsic Value_3Y_min---0.210----------
Intrinsic Value_5Y_max---0.221----------
Intrinsic Value_5Y_min---0.351----------
Market Cap12605778.000-59%19995372.00019995372.0000%36947970.000-46%37542035.400-47%49475505.240-60%30258214.020-34%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio-0.807+37%-1.281-1.2810%-2.925+128%-3.291+157%-5.828+355%-4.117+221%
Pe Ratio-2.439+37%-3.869-3.8690%-5.841+51%-6.116+58%-8.700+125%-7.314+89%
Price Per Share0.290-59%0.4600.4600%0.850-46%0.864-47%1.138-60%0.696-34%
Price To Free Cash Flow Ratio-5.369+37%-8.516-8.5160%-11.772+38%-12.256+44%-17.317+103%-11.246+32%
Price To Total Gains Ratio0.000-59%0.0000.0000%-13.159+80861381%-14.266+87660979%-8.559+52596427%-10.311+63361215%
Quick Ratio--0.0010.0010%-+100%0.004-60%0.009-84%0.006-75%
Return On Assets---26.478-26.4780%-12.609-52%-18.842-29%-21.533-19%-18.999-28%
Return On Equity----0%-0%-0%-0%-0%
Total Gains Per Share--28266.22728266.2270%-0.065+100%9422.040+200%13105.633+116%7590.996+272%
Usd Book Value---15611543.000-15611543.0000%-12633895.000-19%-12690524.333-19%-10352179.200-34%-7702336.700-51%
Usd Book Value Change Per Share---0.069-0.0690%-0.065-6%-0.059-14%-0.049-28%-0.036-48%
Usd Book Value Per Share---0.359-0.3590%-0.291-19%-0.292-19%-0.238-34%-0.177-51%
Usd Dividend Per Share--28266.29628266.2960%-+100%9422.099+200%13105.682+116%7591.032+272%
Usd Enterprise Value--4210861.0004210861.0000%23904230.000-82%24583682.733-83%38903810.040-89%29287117.900-86%
Usd Eps---0.119-0.1190%-0.146+22%-0.138+16%-0.132+11%-0.097-19%
Usd Free Cash Flow---2347891.000-2347891.0000%-3138686.000+34%-2955086.333+26%-2845420.400+21%-2513394.400+7%
Usd Free Cash Flow Per Share---0.054-0.0540%-0.072+34%-0.068+26%-0.065+21%-0.058+7%
Usd Free Cash Flow To Equity Per Share---0.005-0.0050%0.003-255%-0.002-63%0.000-30761%0.000-100%
Usd Market Cap12605778.000-59%19995372.00019995372.0000%36947970.000-46%37542035.400-47%49475505.240-60%30258214.020-34%
Usd Price Per Share0.290-59%0.4600.4600%0.850-46%0.864-47%1.138-60%0.696-34%
Usd Profit---5167748.000-5167748.0000%-5167748.0000%-5269165.333+2%-5156013.4000%-3850857.700-25%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share--28266.22728266.2270%-0.065+100%9422.040+200%13105.633+116%7590.996+272%
 EOD+1 -7MRQTTM+0 -0YOY+13 -183Y+14 -195Y+13 -2010Y+11 -22

3.3 Fundamental Score

Let's check the fundamental score of Cell Source Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.439
Price to Book Ratio (EOD)Between0-1-0.807
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.001
Current Ratio (MRQ)Greater than10.012
Debt to Asset Ratio (MRQ)Less than180.989
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-26.478
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Cell Source Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.290
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Cell Source Inc

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2025-07-04 20:19:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cell Source Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cell Source Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM--140.3%+140.3%
YOY--196.4%+196.4%
3Y--248.5%+248.5%
5Y--343.4%+343.4%
10Y--496.2%+496.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cell Source Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • -2,647.8% Return on Assets means thatΒ Cell Source Inc generatedΒ $-26.48 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cell Source Inc:

  • The MRQ is -2,647.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2,647.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2,647.8%TTM-2,647.8%0.0%
TTM-2,647.8%YOY-1,260.9%-1,386.9%
TTM-2,647.8%5Y-2,153.3%-494.5%
5Y-2,153.3%10Y-1,899.9%-253.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,647.8%-11.6%-2,636.2%
TTM-2,647.8%-11.6%-2,636.2%
YOY-1,260.9%-11.4%-1,249.5%
3Y-1,884.2%-11.8%-1,872.4%
5Y-2,153.3%-12.0%-2,141.3%
10Y-1,899.9%-13.7%-1,886.2%
4.3.1.3. Return on Equity

Shows how efficient Cell Source Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Cell Source Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cell Source Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--15.0%+15.0%
YOY--14.5%+14.5%
3Y--16.9%+16.9%
5Y--17.5%+17.5%
10Y--19.9%+19.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cell Source Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cell Source Inc is operatingΒ .

  • Measures how much profit Cell Source Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cell Source Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.0%+249.0%
YOY--208.5%+208.5%
3Y--223.8%+223.8%
5Y--346.1%+346.1%
10Y--475.5%+475.5%
4.3.2.2. Operating Ratio

Measures how efficient Cell Source Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cell Source Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM-2.684-2.684
YOY-3.096-3.096
3Y-3.652-3.652
5Y-4.745-4.745
10Y-6.614-6.614
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cell Source Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cell Source Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.01Β means the company has $0.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cell Source Inc:

  • The MRQ is 0.012. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.012. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.012TTM0.0120.000
TTM0.012YOY0.031-0.019
TTM0.0125Y0.030-0.017
5Y0.03010Y0.039-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0123.661-3.649
TTM0.0123.846-3.834
YOY0.0314.140-4.109
3Y0.0254.688-4.663
5Y0.0305.746-5.716
10Y0.0396.147-6.108
4.4.3.2. Quick Ratio

Measures if Cell Source Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cell Source Inc:

  • The MRQ is 0.001. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.001. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.001TTM0.0010.000
TTM0.001YOY-+0.001
TTM0.0015Y0.009-0.008
5Y0.00910Y0.006+0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0012.826-2.825
TTM0.0013.182-3.181
YOY-3.786-3.786
3Y0.0044.311-4.307
5Y0.0095.703-5.694
10Y0.0066.454-6.448
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cell Source Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Cell Source IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cell Source Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 80.99Β means that Cell Source Inc assets areΒ financed with 8,098.9% credit (debt) and the remaining percentage (100% - 8,098.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cell Source Inc:

  • The MRQ is 80.989. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 80.989. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ80.989TTM80.9890.000
TTM80.989YOY31.826+49.163
TTM80.9895Y42.945+38.044
5Y42.94510Y37.905+5.040
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ80.9890.329+80.660
TTM80.9890.349+80.640
YOY31.8260.331+31.495
3Y48.3770.340+48.037
5Y42.9450.349+42.596
10Y37.9050.379+37.526
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cell Source Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cell Source Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM-0.437-0.437
YOY-0.414-0.414
3Y-0.450-0.450
5Y-0.464-0.464
10Y-0.515-0.515
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Cell Source Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cell Source Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -3.87 means the investor is paying $-3.87Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cell Source Inc:

  • The EOD is -2.439. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.869. Based on the earnings, the company is expensive. -2
  • The TTM is -3.869. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.439MRQ-3.869+1.430
MRQ-3.869TTM-3.8690.000
TTM-3.869YOY-5.841+1.972
TTM-3.8695Y-8.700+4.831
5Y-8.70010Y-7.314-1.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.439-2.304-0.135
MRQ-3.869-2.080-1.789
TTM-3.869-2.564-1.305
YOY-5.841-3.764-2.077
3Y-6.116-3.773-2.343
5Y-8.700-6.193-2.507
10Y-7.314-6.833-0.481
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cell Source Inc:

  • The EOD is -5.369. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.516. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.516. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.369MRQ-8.516+3.147
MRQ-8.516TTM-8.5160.000
TTM-8.516YOY-11.772+3.255
TTM-8.5165Y-17.317+8.800
5Y-17.31710Y-11.246-6.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.369-3.132-2.237
MRQ-8.516-2.705-5.811
TTM-8.516-3.666-4.850
YOY-11.772-4.405-7.367
3Y-12.256-5.059-7.197
5Y-17.317-8.477-8.840
10Y-11.246-9.304-1.942
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cell Source Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -1.28 means the investor is paying $-1.28Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cell Source Inc:

  • The EOD is -0.807. Based on the equity, the company is expensive. -2
  • The MRQ is -1.281. Based on the equity, the company is expensive. -2
  • The TTM is -1.281. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.807MRQ-1.281+0.473
MRQ-1.281TTM-1.2810.000
TTM-1.281YOY-2.925+1.644
TTM-1.2815Y-5.828+4.547
5Y-5.82810Y-4.117-1.711
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.8071.953-2.760
MRQ-1.2811.843-3.124
TTM-1.2812.112-3.393
YOY-2.9252.441-5.366
3Y-3.2912.494-5.785
5Y-5.8283.661-9.489
10Y-4.1174.311-8.428
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets195
Total Liabilities15,807
Total Stockholder Equity-15,612
 As reported
Total Liabilities 15,807
Total Stockholder Equity+ -15,612
Total Assets = 195

Assets

Total Assets195
Total Current Assets195
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 22
Other Current Assets 173
Total Current Assets  (as reported)195
Total Current Assets  (calculated)195
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,807
Long-term Liabilities0
Total Stockholder Equity-15,612
Total Current Liabilities
Short-term Debt 9,254
Short Long Term Debt 9,254
Accounts payable 1,467
Other Current Liabilities 4,953
Total Current Liabilities  (as reported)15,807
Total Current Liabilities  (calculated)24,928
+/- 9,122
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock40
Retained Earnings -41,667
Other Stockholders Equity 26,014
Total Stockholder Equity (as reported)-15,612
Total Stockholder Equity (calculated)-15,614
+/- 2
Other
Capital Stock42
Cash and Short Term Investments 22
Common Stock Shares Outstanding 37,786
Current Deferred Revenue100,000,000
Liabilities and Stockholders Equity 195
Net Debt 9,232
Net Invested Capital -6,359
Net Working Capital -15,612
Short Long Term Debt Total 9,254



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
22
19
123
368
211
532
66
115
452
314
410
195
195410314452115665322113681231922
   > Total Current Assets 
22
19
121
338
211
532
66
115
452
314
410
195
195410314452115665322113381211922
       Cash And Cash Equivalents 
22
19
19
7
4
371
19
28
245
93
223
22
2222393245281937147191922
       Other Current Assets 
0
63
101
207
207
36
47
87
207
221
23
173
17323221207874736207207101630
   > Long-term Assets 
0
0
2
30
0
0
0
0
4
0
0
0
0004000030200
       Property Plant Equipment 
0
0
2
1
0
0
0
0
0
0
0
0
000000001200
       Long-term Assets Other 
0
0
0
28
0
0
0
0
4
0
0
0
0004000028000
> Total Liabilities 
5
7
3,907
6,126
6,454
5,089
4,986
5,857
8,400
10,140
13,044
15,807
15,80713,04410,1408,4005,8574,9865,0896,4546,1263,90775
   > Total Current Liabilities 
5
7
3,907
6,050
6,454
5,089
4,986
5,712
8,400
10,140
13,044
15,807
15,80713,04410,1408,4005,7124,9865,0896,4546,0503,90775
       Short-term Debt 
258
231
100
1,070
3,088
2,321
2,673
2,553
4,806
6,469
0
9,254
9,25406,4694,8062,5532,6732,3213,0881,070100231258
       Short Long Term Debt 
258
231
100
180
3,088
2,321
2,673
2,453
4,806
6,469
7,904
9,254
9,2547,9046,4694,8062,4532,6732,3213,088180100231258
       Accounts payable 
0
558
0
120
219
202
278
135
193
223
680
1,467
1,46768022319313527820221912005580
       Other Current Liabilities 
5
7
3,806
4,860
3,147
837
2,035
2,905
3,278
3,323
240
4,953
4,9532403,3233,2782,9052,0358373,1474,8603,80675
   > Long-term Liabilities 
0
0
100
76
3,307
0
2,951
145
4,999
3,212,503,000
0
0
003,212,503,0004,9991452,95103,3077610000
       Other Liabilities 
0
0
0
4
0
0
0
0
0
0
0
0
000000004000
       Deferred Long Term Liability 
0
0
0
28
0
0
0
0
0
0
0
0
0000000028000
> Total Stockholder Equity
17
11
-3,784
-5,758
-6,243
-4,557
-4,920
-5,742
-7,947
-9,826
-12,634
-15,612
-15,612-12,634-9,826-7,947-5,742-4,920-4,557-6,243-5,758-3,7841117
   Common Stock
6
6
24
24
25
25
26
27
33
34
36
40
4036343327262525242466
   Retained Earnings -41,667-36,346-31,178-25,706-21,146-16,670-14,553-11,470-10,503-7,998-31-5
   Capital Surplus 
0
0
0
0
0
0
0
0
17,725
0
0
0
00017,72500000000
   Treasury Stock000000000000
   Other Stockholders Equity 
22
3,238
4,191
4,720
5,203
0
11,723
15,376
17,725
21,316
0
26,014
26,014021,31617,72515,37611,72305,2034,7204,1913,23822



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-4,175
Operating Income-4,175-4,175
 
Operating Expense (+$)
Research Development1,996
Selling General Administrative2,179
Selling And Marketing Expenses2,604,748,395
Operating Expense4,1752,604,752,571
 
Net Interest Income (+$)
Interest Income0
Interest Expense-992
Other Finance Cost-269
Net Interest Income-1,261
 
Pretax Income (+$)
Operating Income-4,175
Net Interest Income-1,261
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,168992,410,825
EBIT - interestExpense = -5,168
-992,419,180
-4,175
Interest Expense992
Earnings Before Interest and Taxes (EBIT)-4,175-4,175
Earnings Before Interest and Taxes (EBITDA)-4,175
 
After tax Income (+$)
Income Before Tax-5,168
Tax Provision-0
Net Income From Continuing Ops-5,609-5,168
Net Income-5,168
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses4,175
Total Other Income/Expenses Net-992,415,0001,261
 

Technical Analysis of Cell Source Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cell Source Inc. The general trend of Cell Source Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cell Source Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cell Source Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cell Source Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.3196 < 0.3598 < 0.368.

The bearish price targets are: 0.246 > 0.24 > 0.2322.

Know someone who trades $CLCS? Share this with them.πŸ‘‡

Cell Source Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cell Source Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cell Source Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cell Source Inc.

Cell Source Inc Daily Moving Average Convergence/Divergence (MACD) ChartCell Source Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cell Source Inc. The current adx is .

Cell Source Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cell Source Inc.

Cell Source Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cell Source Inc.

Cell Source Inc Daily Relative Strength Index (RSI) ChartCell Source Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cell Source Inc.

Cell Source Inc Daily Stochastic Oscillator ChartCell Source Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cell Source Inc.

Cell Source Inc Daily Commodity Channel Index (CCI) ChartCell Source Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cell Source Inc.

Cell Source Inc Daily Chande Momentum Oscillator (CMO) ChartCell Source Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cell Source Inc.

Cell Source Inc Daily Williams %R ChartCell Source Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cell Source Inc.

Cell Source Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cell Source Inc.

Cell Source Inc Daily Average True Range (ATR) ChartCell Source Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cell Source Inc.

Cell Source Inc Daily On-Balance Volume (OBV) ChartCell Source Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cell Source Inc.

Cell Source Inc Daily Money Flow Index (MFI) ChartCell Source Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cell Source Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Cell Source Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cell Source Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.290
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cell Source Inc with someone you think should read this too:
  • Are you bullish or bearish on Cell Source Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cell Source Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cell Source Inc

I send you an email if I find something interesting about Cell Source Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cell Source Inc.

Receive notifications about Cell Source Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.